Briefing
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
Industry news: in its November 4, 2026, third-quarter earnings release, BillionToOne said Northstar Clear, a tissue-free, blood-only MRD test it describes as intended for all solid tumors, is planned to be commercially available on December 15, 2026, with initial colorectal cancer data to be compared with a tumor-informed assay.